1,2-dihydroquinoline derivative having substituted phenylchalcogeno lower alkyl group and ester-introduced phenyl group as substituents
View Patent ↗The compounds represented in general formula (1) and a salt thereof are useful for glucocorticoid receptor modulator. The R 1 represents a hydrogen atom or a lower alkyl group; R 2 represents a hydrogen atom or a lower alkyl group; R 3 and R 4 may be the same or different and represent a hydrogen atom or a lower alkyl group; R 5 represents a hydrogen atom or a lower alkyl group; R 6 represents a halogen atom, a lower alkyl group, a hydroxy group, a lower alkoxy group or a nitro group; X represents —C(O)—, —C(O)NR 8 —, —S(O) 2 — and the like; R 7 and/or R 8 may be the same or different and represent a hydrogen atom, a lower alkyl group which may have a substituent, an aryl group which may have a substituent, a heterocyclic group which may have a substituent, a lower alkoxy group which may have a substituent and the like; Y represents a lower alkylene group; Z represents a chalcogen atom; and P represents 0, 1, 2 or 3.
1. A compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof:
wherein R 1 represents a hydrogen atom or a lower alkyl group;
R 2 represents a hydrogen atom or a lower alkyl group;
R 3 and R 4 may be the same or different and represent a hydrogen atom or a lower alkyl group;
R 5 represents a hydrogen atom or a lower alkyl group;
R 6 represents a halogen atom, a lower alkyl group, a hydroxy group, a lower alkoxy group, a nitro group or a cyano group;
X represents —C(O)—, —C(O)NR 8 —, —S(O)— or —S(O) 2 —;
R 7 and/or R 8 may be the same or different and represent a hydrogen atom, a lower alkyl group which may have a substituent, a lower alkenyl group which may have a substituent, a lower alkynyl group which may have a substituent, a lower cycloalkyl group which may have a substituent, an aryl group which may have a substituent, a heterocyclic group which may have a substituent, a lower alkoxy group which may have a substituent, a lower alkenyloxy group which may have a substituent, a lower alkynyloxy group which may have a substituent, a lower cycloalkyloxy group which may have a substituent, an aryloxy group which may have a substituent or a heterocyclic oxy group which may have a subustituent;
Y represents a lower alkylene group;
Z represents a chalcogen atom;
p represents 0, 1, 2 or 3, in the case where p is 2 or 3, each R 6 may be the same or different.
2. The compound or a pharmaceutically acceptable salt thereof according to claim 1 , wherein in the formula (1),
R 1 represents a hydrogen atom or a lower alkyl group;
R 2 represents a hydrogen atom or a lower alkyl group;
R 3 and R 4 may be the same or different and represent a hydrogen atom or a lower alkyl group;
R 5 represents a hydrogen atom or a lower alkyl group;
R 6 represents a halogen atom, a lower alkyl group, a hydroxy group, a lower alkoxy group, a nitro group or a cyano group;
X represents —CO—, —C(O)NR 8 —, —S(O)— or —S(O) 2 —;
R 7 and/or R 8 may be the same or different and represent a hydrogen atom, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower cycloalkyl group, an aryl group, a heterocyclic group, a lower alkoxy group, a lower alkenyloxy group, a lower alkynyloxy group, a lower cycloalkyloxy group, an aryloxy group or a heterocyclic oxy group;
in the case where R 7 and/or R 8 is a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower alkoxy group, a lower alkenyloxy group or a lower alkynyloxy group, the lower alkyl group, lower alkenyl group, lower alkynyl group, lower alkoxy group, lower alkenyloxy group or lower alkynyloxy group may have one or a plurality of groups selected from a halogen atom, a lower cycloalkyl group, an aryl group, a heterocyclic group, a hydroxy group, a lower alkoxy group, a lower alkenyloxy group, a lower alkynyloxy group, a lower cycloalkyloxy group, an aryloxy group, a heterocyclic oxy group and —NR a R b as substituent(s);
in the case where R 7 and/or R 8 is a lower cycloalkyl group, an aryl group, a heterocyclic group, a lower cycloalkyloxy group, an aryloxy group or a heterocyclic oxy group, the lower cycloalkyl group, aryl group, heterocyclic group, lower cycloalkyloxy group, aryloxy group or heterocyclic oxy group may have one or a plurality of groups selected from a halogen atom, a lower alkyl group, a halogenated lower alkyl group, an aryl group, a lower alkenyl group, a lower alkynyl group, a lower cycloalkyl group, an aryl group, a heterocyclic group, a hydroxy group, a lower alkoxy group, a halogenated lower alkoxy group, a lower alkenyloxy group, a lower alkynyloxy group, a lower cycloalkyloxy group, an aryloxy group, a heterocyclic oxy group, a mercapto group, a lower alkylthio group, a lower alkenylthio group, a lower alkynylthio group, a lower cycloalkylthio group, an arylthio group, a heterocyclic thio group, a lower alkylcarbonyl group, an arylcarbonyl group, a lower alkoxycarbonyl group, an aryloxycarbonyl group, a lower alkylcarbonyloxy group, an arylcarbonyloxy group, —NR a R b , a nitro group and a cyano group as substituent(s);
R a and R b may be the same or different and represent a hydrogen atom, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower cycloalkyl group, an aryl group, a heterocyclic group, a lower alkoxycarbonyl group or an aryloxycarbonyl group;
Y represents a lower alkylene group;
Z represents a chalcogen atom;
p represents 0, 1, 2 or 3, in the case where p is 2 or 3, each R 6 may be the same or different.
3. The compound or a pharmaceutically acceptable salt thereof according to claim 1 , wherein in the formula (1),
R 1 represents a hydrogen atom or a lower alkyl group;
R 2 represents a hydrogen atom or a lower alkyl group;
R 3 and R 4 may be the same or different and represent a hydrogen atom or a lower alkyl group;
R 5 represents a hydrogen atom or a lower alkyl group;
R 6 represents a halogen atom, a lower alkyl group, a hydroxy group, a lower alkoxy group or a nitro group;
X represents —CO—, —C(O)NR 8 —, —S(O)— or —S(O) 2 —;
R 7 and/or R 8 may be the same or different and represent a hydrogen atom, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower cycloalkyl group, an aryl group, a heterocyclic group, a lower alkoxy group, a lower alkenyloxy group, a lower alkynyloxy group, a lower cycloalkyloxy group, an aryloxy group or a heterocyclic oxy group;
in the case where R 7 and/or R 8 is a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower alkoxy group, a lower alkenyloxy group or a lower alkynyloxy group, the lower alkyl group, lower alkenyl group, lower alkynyl group, lower alkoxy group, lower alkenyloxy group or lower alkynyloxy group may have one or a plurality of groups selected from a halogen atom, a lower cycloalkyl group, an aryl group, a heterocyclic group, a hydroxy group, a lower alkoxy group, a lower cycloalkyloxy group, an aryloxy group, a heterocyclic oxy group and —NR a R b as substituent(s);
in the case where R 7 and/or R 8 is a lower cycloalkyl group, an aryl group, a heterocyclic group, a lower cycloalkyloxy group, an aryloxy group or a heterocyclic oxy group, the lower cycloalkyl group, aryl group, heterocyclic group, lower cycloalkyloxy group, aryloxy group or heterocyclic oxy group may have one or a plurality of groups selected from a halogen atom, a lower alkyl group, a halogenated lower alkyl group, a lower cycloalkyl group, an aryl group, a hydroxy group, a lower alkoxy group, a halogenated lower alkoxy group, a lower cycloalkyloxy group, an aryloxy group, a mercapto group, a lower alkylthio group, a lower cycloalkylthio group, an arylthio group, a heterocyclic thio group, a lower alkylcarbonyl group, an arylcarbonyl group, a lower alkoxycarbonyl group, an aryloxycarbonyl group, a lower alkylcarbonyloxy group, an arylcarbonyloxy group, —NR a R b , a nitro group and a cyano group as substituent(s);
R a and R b may be the same or different and represent a hydrogen atom, a lower alkyl group or a lower alkoxycarbonyl group;
Y represents a lower alkylene group;
Z represents an oxygen atom or a sulfur atom;
p represents 0, 1, 2 or 3, in the case where p is 2 or 3, each R 6 may be the same or different.
4. The compound or a pharmaceutically acceptable salt thereof according to claim 1 , wherein in the formula (1),
R 1 represents a lower alkyl group;
R 2 represents a hydrogen atom;
R 3 and R 4 represent a lower alkyl group;
R 5 represents a lower alkyl group;
R 6 represents a halogen atom, a lower alkyl group, a hydroxy group, a lower alkoxy group or a nitro group;
X represents —CO—, —C(O)NR 8 — or —S(O) 2 —;
R 7 represents a lower alkyl group, a lower alkenyl group, a lower cycloalkyl group, an aryl group, a heterocyclic group, a lower alkoxy group or an aryloxy group;
in the case where R 7 is a lower alkyl group or a lower alkoxy group, the lower alkyl group or lower alkoxy group may have one or a plurality of groups selected from a halogen atom, an aryl group, a heterocyclic group, a lower alkoxy group and —NR a R b as substituent(s);
in the case where R 7 is an aryl group, a heterocyclic group or an aryloxy group, the aryl group, heterocyclic group or aryloxy group may have one or a plurality of groups selected from a halogen atom, a lower alkyl group, a halogenated lower alkyl group, an aryl group, a hydroxy group, a lower alkoxy group, a halogenated lower alkoxy group, a lower alkylthio group, a lower alkylcarbonyl group, a lower alkoxycarbonyl group, a lower alkylcarbonyloxy group, —NR a R b , a nitro group and a cyano group as substituent(s);
R a and R b may be the same or different and represent a hydrogen atom, a lower alkyl group or a lower alkoxycarbonyl group;
R 8 represents a hydrogen atom or a lower alkyl group;
in the case where R 8 is a lower alkyl group, the lower alkyl group may have one or a plurality of groups selected from an aryl group or a heterocyclic group as substituent(s);
Y represents a lower alkylene group;
Z represents an oxygen atom;
p represents 0, 1 or 2, in the case where p is 2, each R 6 may be the same or different.
5. The compound or a pharmaceutically acceptable salt thereof according to claim 1 , wherein in the formula (1),
R 1 represents a lower alkyl group;
R 2 represents a hydrogen atom;
R 3 and R 4 represent a lower alkyl group;
R 5 represents a lower alkyl group;
R 6 represents a halogen atom, a lower alkyl group, a hydroxy group, a lower alkoxy group or a nitro group;
X represents —CO—, —C(O)NR 8 — or —S(O) 2 —;
R 7 represents a lower alkyl group, a lower alkenyl group, a lower cycloalkyl group, an aryl group, a heterocyclic group, a lower alkoxy group or an aryloxy group;
in the case where R 7 is a lower alkyl group, the lower alkyl group may have one or a plurality of groups selected from a halogen atom, an aryl group, a heterocyclic group, a lower alkoxy group and —NR a R b as substituent(s);
in the case where R 7 is an aryl group, the aryl group may have one or a plurality of groups selected from a halogen atom, a lower alkyl group, a halogenated lower alkyl group, a lower alkoxy group, a halogenated lower alkoxy group, a lower alkylthio group, a lower alkylcarbonyl group, a lower alkoxycarbonyl group, a lower alkylcarbonyloxy group, —NR a R b , a nitro group and a cyano group as substituent(s);
in the case where R 7 is a heterocyclic group, the heterocyclic group may have one or a plurality of groups selected from a halogen atom, a lower alkyl group, an aryl group, a hydroxy group, a lower alkoxy group, a lower alkylthio group, a lower alkylcarbonyl group, a lower alkoxycarbonyl group or a nitro group as substituent(s);
in the case where R 7 is a lower alkoxy group, the lower alkoxy group may have one or a plurality of groups selected from a halogen atom and an aryl group as substituent(s);
in the case where R 7 is an aryloxy group, the aryloxy group may have one or a plurality of groups selected from a halogen atom and a lower alkoxy group as substituent(s);
R a and R b may be the same or different and represent a hydrogen atom, a lower alkyl group or a lower alkoxycarbonyl group;
R 8 represents a hydrogen atom or a lower alkyl group;
in the case where R 8 is a lower alkyl group, the lower alkyl group may have one or a plurality of groups selected from an aryl group or a heterocyclic group as substituent(s);
Y represents a lower alkylene group;
Z represents an oxygen atom;
p represents 0, 1 or 2, in the case where p is 2, each R 6 may be the same or different.
6. The compound or a pharmaceutically acceptable salt thereof according to claim 1 , wherein in the formula (1), Z represents an oxygen atom.
7. The compound or a pharmaceutically acceptable salt thereof according to claim 1 , wherein in the formula (1), R 1 , R 3 , R 4 and R 5 represent a methyl group; R 2 represents a hydrogen atom; Y represents a methylene group.
8. A pharmaceutical composition, comprising the compound or a pharmaceutically acceptable salt thereof according to claim 1 and a pharmaceutically acceptable carrier.
9. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-(4-benzoyloxy-2-methoxyphenyl)-5-(5-fluoro-2-methylphenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
10. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-(4-t-butoxycarbonylaminoacetoxy-2-methoxyphenyl)-5-(5-fluoro-2-methylphenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
11. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-[2-methoxy-4-(4-methoxybenzoyloxy)phenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
12. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-[2-methoxy-4-(3-methoxybenzoyloxy)phenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
13. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-[2-methoxy-4-(2-methoxybenzoyloxy)phenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
14. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-[4-(2-chlorobenzoyloxy)-2-methoxyphenyl]-5-(5-fluoro-2-methylphenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
15. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-(4-cyclohexylcarbonyloxy-2-methoxyphenyl)-5-(5-fluoro-2-methylphenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
16. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-[2-methoxy-4-(pyridin-3-ylcarbonyloxy)phenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
17. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-(4-butyryloxy-2-methoxyphenyl)-5-(5-fluoro-2-methylphenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
18. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-(2-methoxy-4-propionyloxyphenyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
19. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-(4-acryloyloxy-2-methoxyphenyl)-5-(5-fluoro-2-methylphenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
20. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-[2-methoxy-4-(thiophen-3-ylcarbonyloxy)phenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
21. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-[4-(furan-2-ylcarbonyloxy)-2-methoxyphenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
22. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-(4-isobutyryloxy-2-methoxyphenyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
23. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-(2-methoxy-4-phenylacetoxyphenyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
24. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-(2-methoxy-5-propionyloxyphenyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
25. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-[2-methoxy-4-(thiophen-2-ylcarbonyloxy)phenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
26. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-[2-methoxy-4-(3-phenylpropionyloxy)phenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
27. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-[4-(furan-3-ylcarbonyloxy)-2-methoxyphenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
28. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-[2-methoxy-4-(pyridin-2-ylcarbonyloxy)phenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
29. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-[2-methoxy-4-(4-nitrobenzoyloxy)phenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
30. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-[2-methoxy-4-(pyridin-4-ylcarbonyloxy)phenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
31. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-[2-methoxy-5-(pyridin-2-ylcarbonyloxy)phenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
32. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-[2-methoxy-5-(pyridin-4-ylcarbonyloxy)phenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
33. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-[4-(2-acetoxybenzoyloxy)-2-methoxyphenyl]-5-(5-fluoro-2-methylphenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
34. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-[4-(1-t-butoxycarbonylpiperidin-4-ylcarbonyloxy)-2-methoxyphenyl]-5-(5-fluoro-2-methylphenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
35. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-[2-methoxy-4-(2-methylthiobenzoyloxy)phenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
36. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-[4-(1-t-butoxycarbonylimidazol-4-ylcarbonyloxy)-2-methoxyphenyl]-5-(5-fluoro-2-methylphenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
37. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-[2-methoxy-4-(thiazol-4-ylcarbonyloxy)phenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
38. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-[2-methoxy-4-(thiazol-5-ylcarbonyloxy)phenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
39. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-[2-methoxy-4-(oxazol-4-ylcarbonyloxy)phenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
40. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-[4-(3-acetylbenzoyloxy)-2-methoxyphenyl]-5-(5-fluoro-2-methylphenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
41. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-[4-(2-fluorobenzoyloxy)-2-methoxyphenyl]-5-(5-fluoro-2-methylphenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
42. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-[4-(3-fluorobenzoyloxy)-2-methoxyphenyl]-5-(5-fluoro-2-methylphenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
43. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-[2-methoxy-4-(5-methylfuran-2-ylcarbonyloxy)phenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
44. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-[2-methoxy-4-(2-methylpyridin-3-ylcarbonyloxy)phenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
45. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-[2-methoxy-4-(pyridin-3-ylacetoxy)phenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
46. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-[4-(4-acetylbenzoyloxy)-2-methoxyphenyl]-5-(5-fluoro-2-methylphenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
47. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-[2-methoxy-4-(3-methoxycarbonylbenzoyloxy)phenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
48. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-[2-methoxy-4-(6-methylpyridin-3-ylcarbonyloxy)phenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
49. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-[2-methoxy-4-(4-methylpyridin-3-ylcarbonyloxy)phenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
50. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-[2-methoxy-4-(3-methylfuran-2-ylcarbonyloxy)phenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
51. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-(4-t-butylcarbonyloxy-2-methoxyphenyl)-5-(5-fluoro-2-methylphenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
52. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-[2-methoxy-4-(pyrimidin-5-ylcarbonyloxy)phenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
53. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-[2-methoxy-4-(5-nitrofuran-2-ylcarbonyloxy)phenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
54. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-[4-(2-chloropyridin-4-ylcarbonyloxy)-2-methoxyphenyl]-5-(5-fluoro-2-methylphenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
55. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-[4-(3-fluoropyridin-4-ylcarbonyloxy)-2-methoxyphenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
56. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-[2-methoxy-4-(2-methoxybenzoyloxy)phenyl]-5-(2-methyl-5-nitrophenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
57. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-[2-methoxy-4-(pyridin-3-ylcarbonyloxy)phenyl]-5-(2-methyl-5-nitrophenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
58. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-[4-(furan-2-ylcarbonyloxy)-2-methoxyphenyl]-5-(2-methyl-5-nitrophenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
59. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-[4-(2-chlorobenzoyloxy)-2-methoxyphenyl]-5-(2-methoxy-5-nitrophenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
60. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-[2-methoxy-4-(2-methylpyridin-3-ylcarbonyloxy)phenyl]-5-(2-methoxy-5-nitrophenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
61. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-[2-methoxy-4-(2-methoxybenzoyloxy)phenyl]-5-(2-methoxy-5-nitrophenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
62. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(2-methoxy-5-nitrophenoxymethyl)-6-[2-methoxy-4-(thiophen-3-ylcarbonyloxy)phenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
63. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-[4-(furan-3-ylcarbonyloxy)-2-methoxyphenyl]-5-(2-methyl-5-nitrophenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
64. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-[2-methoxy-4-(2-methylpyridin-3-ylcarbonyloxy)phenyl]-5-(2-methyl-5-nitrophenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
65. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-[2-methoxy-4-(2-methoxypyridin-3-ylcarbonyloxy)phenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
66. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-(4-aminoacetoxy-2-methoxyphenyl)-5-(5-fluoro-2-methylphenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
67. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-(2-methoxy-4-propylsulfonyloxyphenyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
68. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-(4-ethylsulfonyloxy-2-methoxyphenyl)-5-(5-fluoro-2-methylphenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
69. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-(4-isopropylsulfonyloxy-2-methoxyphenyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
70. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-(4-butylsulfonyloxy-2-methoxyphenyl)-5-(5-fluoro-2-methylphenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
71. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(2-methoxy-5-nitrophenoxymethyl)-6-(2-methoxy-4-propylsulfonyloxyphenyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
72. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-(4-cyclopropylsulfonyloxy-2-methoxyphenyl)-5-(2-methoxy-5-nitrophenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
73. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-(4-isopropylsulfonyloxy-2-methoxyphenyl)-5-(2-methoxy-5-nitrophenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
74. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-(4-ethylsulfonyloxy-2-methoxyphenyl)-5-(2-methyl-5-nitrophenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
75. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-(2-methoxy-4-propylsulfonyloxyphenyl)-5-(2-methyl-5-nitrophenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
76. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-(4-isopropylsulfonyloxy-2-methoxyphenyl)-5-(2-methyl-5-nitrophenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
77. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-(4-cyclopropylsulfonyloxy-2-methoxyphenyl)-5-(5-fluoro-2-methylphenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
78. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-(4-isobutylsulfonyloxy-2-methoxyphenyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
79. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-(4-cyclopentylsulfonyloxy-2-methoxyphenyl)-5-(5-fluoro-2-methylphenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
80. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-[2-methoxy-4-(3,3,3-trifluoropropylsulfonyloxy)phenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
81. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-[2-methoxy-4-(2-methoxyphenoxycarbonyloxy)phenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
82. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-[4-(2-chlorophenylaminocarbonyloxy)-2-methoxyphenyl]-5-(5-fluoro-2-methylphenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
83. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-[2-methoxy-4-(3-methoxyphenylaminocarbonyloxy)phenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
84. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-[2-methoxy-4-(4-methoxyphenylaminocarbonyloxy)phenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
85. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-[2-methoxy-4-(4-methoxycarbonylphenylaminocarbonyloxy)phenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
86. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-(4-dimethylaminocarbonyloxy-2-methoxyphenyl)-5-(5-fluoro-2-methylphenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
87. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-[4-(4-cyanophenylaminocarbonyloxy)-2-methoxyphenyl]-5-(5-fluoro-2-methylphenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
88. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 5-(5-fluoro-2-methylphenoxymethyl)-6-[2-methoxy-4-(morpholin-4-ylcarbonyloxy)phenyl]-2,2,4-trimethyl-1,2-dihydroquinoline.
89. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-(4-isopropylaminocarbonyloxy-2-methoxyphenyl)-5-(5-fluoro-2-methylphenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
90. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-[2-methoxy-4-(morpholin-4-ylcarbonyloxy)phenyl]-5-(2-methoxy-5-nitrophenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
91. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-[2-methoxy-4-(morpholin-4-ylcarbonyloxy)phenyl]-5-(2-methyl-5-nitrophenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
92. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-(4-dimethylaminocarbonyloxy-2-methoxyphenyl)-5-(2-methyl-5-nitrophenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
93. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-[4-[N-benzyl-N-(2-dimethylaminoethyl)aminocarbonyloxy]-2-methoxyphenyl]-5-(5-fluoro-2-methylphenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
94. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-[4-[N-(2-dimethylaminoethyl)-N-(pyridin-3-ylmethyl)aminocarbonyloxy]-2-methoxyphenyl]-5-(5-fluoro-2-methylphenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.
95. The compound or a pharmaceutically acceptable salt according to claim 1 , wherein the compound is 6-[4-[N-(2-dimethylaminoethyl)-N-ethylaminocarbonyloxy]-2-methoxyphenyl]-5-(5-fluoro-2-methylphenoxymethyl)-2,2,4-trimethyl-1,2-dihydroquinoline.